香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司第九屆監事會第十四次會議決議公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年8月15日 於本公告日，本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2025-057 广州白云山医药集团股份有限公司 第九届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"本公司"）第九届监 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司第九屆董事會第二十八次會議決議公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年8月15日 於本公告日，本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2025－056 广州白云山医药集团股份有限公司 第九届董事会第二十八次会议决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"本公司"）第九 ...

格隆汇8月15日丨白云山(00874.HK)公告，董事会建议委任陈杰辉为公司第九届董事会执行董事。 ...

EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | | 股票發行人現金股息公告 | | 發行人名稱 | 廣州白雲山醫藥集團股份有限公司 | | 股份代號 | 00874 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止半年度之中期股息 | | 公告日期 | 2025年8月15日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 股 0.4 RMB | | 股東批准日期 | 2025年6月3日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.4399 HKD | | 匯率 | 1 ...

陳傑輝先生，50歲，中共黨員，博士研究生學歷，法學碩士。陳先生於1995年7月參加工作，曾先後 擔任廣州市地方稅務局辦公室副主任科員、主任科員、副主任，廣州市天河區地方稅務局副局長， 廣州市地方稅務局、國家稅務總局廣州市稅務局辦公室主任；廣州輕工工貿集團有限公司副總經 理、總法律顧問，兼廣州市大新文化創意發展有限公司董事長等職務；現任廣州醫藥集團有限公司 （「廣藥集團」）黨委副書記、副董事長、總經理、工會主席，本公司黨委副書記、工會主席。陳先生 在戰略管理、企業管理、公司治理、合規管理和黨建工作等方面有豐富的經驗。 任期 待陳先生的委任獲本公司股東批准後，本公司將與他簽訂服務合約，任期自股東於股東大會上批准 之日起至本公司第九屆董事會任期屆滿止。根據本公司的《公司章程》，陳先生可於任期結束後有資 格於本公司股東大會上重選連任。 1 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 建議委任執行董事 本公告乃廣州白雲山醫藥集團股份有限公司（「本公司」）董 ...

建議修訂《公司章程》《股東大會議事規則》《董事會議事規則》 並取消監事會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 本公告是由本公司根據《香港上市規則》第13.51(1)條發出的。 公司謹此宣佈，董事會已於2025年8月15日決議向股東建議對《公司章程》《股東大會議事規則》及《董 事會議事規則》作出若干修訂並取消監事會。 建議修訂《公司章程》 2024年7月1日，《公司法》生效實施。中國證監會發佈《關於新<公司法>配套制度規則實施相關過渡 期安排》以及《章程指引》等相關法律、行政法規和規範性文件，並自發佈之日起生效實施。鑒於上述 法律、行政法規和規範性文件的變化，並結合實際情況，本公司建議對現行《公司章程》進行修訂。 1 建議修訂《公司章程》主要包括(1)將《公司章程》中有關「股東大會」的表述統一調整為「股東會」；(2)進 一步明確股東會、董事會決策權限及範圍；(3)刪除監事會相關章節及內容；(4)將「審核委員會」更名 為「審計委員會」，並行使 ...

Core Viewpoint - Baiyunshan (00874) reported a slight increase in revenue for the first half of 2025, but a decrease in net profit, indicating challenges in demand and competition within the industry [1] Financial Performance - The company's revenue for the first half of 2025 was approximately 41.835 billion yuan, representing a year-on-year growth of 1.93% [1] - The net profit attributable to shareholders was about 2.516 billion yuan, showing a year-on-year decrease of 1.31% [1] - Basic earnings per share were reported at 1.548 yuan, with a proposed cash dividend of 0.40 yuan per share (tax included) [1] Industry Challenges - The decline in profit compared to the previous year is primarily attributed to insufficient demand, intensified industry competition, and ongoing industry policy impacts [1] - The performance of certain business segments within the group has also experienced a downturn [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 內地個人及企業投資者通過滬港通或深港通投資香港聯交所上市股票的股東應付股息以人民幣 派發，並由本公司委託中國證券登記結算有限公司上海分公司及深圳分公司（「中登公司」）進行派 發，相關股息將於2025年9月26日（星期五）由本公司發放至中登公司，並由中登公司統一派發。 (3) 根據《中華人民共和國企業所得稅法》以及《中華人民共和國企業所得稅法實施條例》（統稱「稅 法」）的規定，自2008年1月1日起，凡中國境內企業向非居民企業股東派發股息時，需代扣代繳 企業所得稅，並以支付人為扣繳義務人。因此，本公司向2025年9月8日（星期一）名列於H股股東 名冊上的非居民企業股東派發2025年中期股息時，有義務代扣代繳10%的企業所得稅；向2025年 9月8日（星期一）名列於H股股東名冊上的居民企業股東派發2025年中期股息時，無代扣代繳企業 所得稅的義務。名列在本公司H股股東名冊上的依法在中國境內成立，或者依照外國 ...

[Important Notice](index=1&type=section&id=%E4%B8%80%E3%80%81%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) [Dividend Distribution Plan](index=1&type=section&id=1.1%20%E8%82%A1%E6%81%AF%E5%88%86%E9%85%8D%E9%A0%90%E6%A1%88) The Board resolved to distribute a cash dividend of RMB 0.40 per share (tax inclusive) to all shareholders, totaling RMB 650,316,379.60 (tax inclusive), with no bonus shares or capital reserve conversion H1 2025 Dividend Distribution Plan | Indicator | Value | | :--- | :--- | | Cash Dividend Per Share (Tax Incl.) | RMB 0.40 | | Total Share Capital (As of Jun 30, 2025) | 1,625,790,949 shares | | Total Proposed Cash Dividend (Tax Incl.) | RMB 650,316,379.60 | | Bonus Shares | None | | Capital Reserve Conversion to Share Capital | None | [Report Description and Board Statement](index=1&type=section&id=1.2%20%E5%A0%B1%E5%91%8A%E8%AA%AA%E6%98%8E%E8%88%87%E8%91%A3%E4%BA%8B%E6%9C%83%E8%81%B2%E6%98%8E) This summary is extracted from the company's H1 2025 report, with the Board, Supervisory Committee, and senior management guaranteeing its truthfulness, accuracy, and completeness; the financial report for this period is unaudited and prepared under China Accounting Standards, with the Chinese version prevailing - This interim report summary is extracted from the full 2025 interim report, investors are advised to read the full report carefully[5](index=5&type=chunk) - The Board, Supervisory Committee, and their directors, supervisors, and senior management guarantee the truthfulness, accuracy, and completeness of this summary and assume legal responsibility[5](index=5&type=chunk) - The Group's and the company's financial reports for this period are prepared under China Accounting Standards and are unaudited[7](index=7&type=chunk) [Board of Directors Composition](index=1&type=section&id=1.3%20%E8%91%A3%E4%BA%8B%E6%9C%83%E6%88%90%E5%93%A1%E6%A7%8B%E6%88%90) As of the announcement date, the company's Board comprises five executive directors and four independent non-executive directors, all of whom attended the 28th meeting of the Ninth Board of Directors - Board members include executive directors Li Xiaojun, Cheng Ning, Cheng Hongjin, Tang Heping, Li Hong, and independent non-executive directors Chen Yajin, Huang Min, Huang Longde, Sun Baoqing[5](index=5&type=chunk) - All directors attended the 28th meeting of the Ninth Board of Directors, with three independent non-executive directors participating via telecommunication[5](index=5&type=chunk) [Definitions](index=2&type=section&id=%E4%BA%8C%E3%80%81%E9%87%8B%E7%BE%A9) This section defines common terms used in the report, including company names, geographical areas, reporting periods, group entities, management bodies, regulatory agencies, and business-related professional terms Definitions of Key Terms | Term | Definition | | :--- | :--- | | Company/This Company/GPHL Baiyunshan | Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | | Reporting Period | January 1, 2025 to June 30, 2025 | | GPHL | Guangzhou Pharmaceutical Group Co., Ltd., the company's controlling shareholder | | S2B2C | Suppliers to Business to Customers, a one-stop service system from industry to business to end-users, directly reaching individual consumers | | ERP | Enterprise Resource Planning, an information technology-based systematic management platform | | SPD | Supply Processing Distribution, a medical SPD supply chain management model | [Company Profile](index=5&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) [Company Introduction](index=5&type=section&id=3.1%20%E5%85%AC%E5%8F%B8%E7%B0%A1%E4%BB%8B) The company is listed on the Shanghai Stock Exchange (A-shares) and The Stock Exchange of Hong Kong Limited (H-shares) under the stock name 'Baiyunshan', with contact information for the Board Secretary and Securities Affairs Representative, along with registered address and website Company Listing Information | Indicator | A-shares | H-shares | | :--- | :--- | :--- | | Stock Abbreviation | Baiyunshan | Baiyunshan | | Stock Code | 600332 | 00874 | | Listing Exchange | Shanghai Stock Exchange | The Stock Exchange of Hong Kong Limited | - The company's registered and office address is No. 45 Shamian North Street, Liwan District, Guangzhou, Guangdong Province, China, and its principal place of business in Hong Kong is Room 2005, 20th Floor, Tower 2, Lippo Centre, 89 Queensway, Hong Kong[11](index=11&type=chunk) [Key Accounting Data and Financial Indicators](index=6&type=section&id=3.2%20%E4%B8%BB%E8%A6%81%E6%9C%83%E8%A8%88%E6%95%B8%E6%93%9A%E5%92%8C%E8%B2%A1%E5%8B%99%E6%8C%87%E6%A8%99) During the reporting period, the company's operating revenue increased by 1.93% year-on-year, but total profit and net profit attributable to parent company shareholders decreased by 4.30% and 1.31% respectively; net cash flow from operating activities significantly dropped by 66.79% due to lower cash collection and increased procurement payments, while net assets and total assets continued to grow Key Accounting Data (Current Period vs. Prior Period) | Indicator | Current Period (RMB Yuan) | Prior Period (RMB Yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 41,834,546,114 | 41,042,815,088 | 1.93 | | Total Profit | 3,090,416,329 | 3,229,403,377 | (4.30) | | Net Profit Attributable to Parent Company Shareholders | 2,516,140,987 | 2,549,565,302 | (1.31) | | Net Cash Flow from Operating Activities | (3,397,136,268) | (2,036,740,495) | (66.79) | Key Financial Indicators (Current Period vs. Prior Period) | Indicator | Current Period | Prior Period | YoY Change | | :--- | :--- | :--- | :--- | | Basic EPS (RMB/share) | 1.548 | 1.568 | (1.31)% | | Diluted EPS (RMB/share) | 1.548 | 1.568 | (1.31)% | | Weighted Average ROE (%) | 6.77 | 7.04 | Decrease of 0.27 percentage points | - Net cash flow from operating activities decreased by **66.79%** year-on-year, primarily due to lower cash collection and increased procurement payments[14](index=14&type=chunk) [Top Ten Shareholders' Holdings](index=8&type=section&id=3.3%20%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E6%9D%B1%E6%8C%81%E8%82%A1%E6%83%85%E6%B3%81) As of the end of the reporting period, the company had 85,550 shareholders; controlling shareholder GPHL held 45.04% of shares, and HKSCC Nominees Limited was the second largest shareholder with 13.52% - As of the end of the reporting period, the total number of shareholders was **85,550 households**[15](index=15&type=chunk) Top Ten Shareholders' Holdings | Shareholder Name | Shareholder Type | Approx. % of Total Share Capital | Number of Shares Held | | :--- | :--- | :--- | :--- | | GPHL | State-owned Legal Person | 45.04 | 732,305,103 | | HKSCC Nominees Limited | Overseas Legal Person | 13.52 | 219,783,142 | | Guangzhou Chengfa | Other | 4.16 | 67,576,183 | | China Securities Finance Corporation Limited | State-owned Legal Person | 2.91 | 47,277,962 | [Preferred Shareholder Information](index=9&type=section&id=3.4%20%E5%84%AA%E5%85%88%E8%82%A1%E8%82%A1%E6%9D%B1%E6%83%85%E6%B3%81) As of the end of the reporting period, the company had no preferred shareholders - As of the end of the reporting period, the company had no preferred shareholders[17](index=17&type=chunk) [Changes in Controlling Shareholder or Actual Controller](index=9&type=section&id=3.5%20%E6%8E%A7%E

Core Insights - The sales of diesel engines in China for July 2025 reached 367,200 units, showing a month-on-month decline of 11.39% but a year-on-year increase of 6.68% [1] - Cumulatively, from January to July 2025, diesel engine sales totaled 3.0322 million units, marking a year-on-year growth of 4.45% [1] - The commercial vehicle market experienced a decline in production and sales in July, with production at 298,000 units and sales at 306,000 units, reflecting month-on-month decreases of 15.8% and 17.1%, respectively, but year-on-year increases of 16.3% and 14.1% [1] Diesel Engine Sales Performance - In July 2025, multi-cylinder diesel engine sales were 139,400 units, down 16.71% month-on-month but up 12.84% year-on-year [7] - From January to July 2025, cumulative sales of multi-cylinder diesel engines reached 1.1621 million units, with a year-on-year growth of 3.55% [7] - The top ten companies accounted for 88.26% of total sales, showing a slight decrease compared to the previous period [7] Company Rankings and Performance - Weichai maintained its leading position with July sales of 53,900 units, achieving a month-on-month growth of 17.13% [4] - Yuchai ranked second with sales of 44,600 units, while Anhui Quanchai and Yunnei ranked third and fourth with sales of 21,000 and 19,900 units, respectively [3][4] - Cumulatively, from January to July 2025, Weichai sold 430,400 units, Yuchai 352,700 units, and Yunnei 213,100 units, with market shares of 17.61%, 14.43%, and 8.72%, respectively [6][10] Market Trends - The overall market for multi-cylinder diesel engines showed fluctuations, with most companies experiencing month-on-month declines in July [3] - The cumulative sales growth of leading companies indicates a competitive landscape, with some companies like Yuchai showing significant year-on-year growth [6][10] - The industry is facing challenges such as market saturation and increased competition, prompting companies to innovate and enhance service offerings [3]